Aptevo Therapeutics Inc SEC Filings

Aptevo Therapeutics Inc. is registering up to 6,903,755 shares of common stock for resale by YA II PN, LTD. under a standby equity purchase agreement. These shares relate to an up to $25.0 million equity line Aptevo entered into with YA on June 16, 2025, under which YA buys shares from Aptevo at 96% of the lowest three-day VWAP during each pricing period. Aptevo will not receive any proceeds from YA’s resale of these shares.

As of September 30, 2025, Aptevo had 13,808,966 shares outstanding, and if all registered shares are issued, total shares outstanding would rise to 20,712,721. The company has already raised approximately $15.0 million under a prior registration and expects to use any additional proceeds from future sales to YA for pipeline development, new programs, business development, and general corporate purposes. The structure may lead to substantial dilution and stock price volatility, and the filing details Nasdaq listing and going-concern related risks.

Aptevo Therapeutics (APVO) director reported an open‑market purchase on Form 4. The filing shows a buy of 13,513 shares of common stock at $1.49 per share on 11/10/2025 (Transaction Code: P). Following the trade, the director beneficially owns 13,514 shares, held directly.

Aptevo Therapeutics (APVO) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $7.5 million and a nine‑month net loss of $20.2 million. Operating expenses rose as R&D reached $4.0 million and G&A was $3.6 million for the quarter. A warrant down‑round adjustment recorded a $1.5 million deemed dividend, increasing loss attributable to common stockholders.

Cash and cash equivalents were $21.1 million at September 30, 2025, up from $8.7 million year‑end, driven by $32.7 million year‑to‑date financing cash inflows. The company raised $18.7 million, net in Q3 via its SEPA with Yorkville and ATM program, plus $4.1 million net after quarter‑end. Stockholders’ equity improved to $17.4 million. Year‑to‑date operating cash use was $20.4 million.

Financing capacity includes $10.0 million remaining under the SEPA; the ATM currently has no availability under Form S‑3 I.B.6 limits. Common warrants outstanding totaled 12,535,033, all exercisable. The company effected a 1‑for‑20 reverse split in May 2025. Clinical updates highlight mipletamig AML combination data with high remission rates and no CRS among evaluable frontline patients. Shares outstanding were 16,850,494 as of November 6, 2025.

Aptevo Therapeutics Inc. (APVO) filed an 8-K stating it furnished a press release announcing its financial results for the period ended September 30, 2025. The press release is included as Exhibit 99.1.

The company notes the information is being furnished under Item 2.02 and is not deemed “filed” for purposes of the Exchange Act or the Securities Act, and will not be incorporated by reference into other SEC filings except by specific reference.

Aptevo Therapeutics entered into Amendment No. 5 to its Rights Agreement, extending the definition of the “Final Expiration Date” to October 29, 2026. The Rights Agreement covers contingent rights to purchase one one‑thousandth of a share of the company’s Series A Junior Participating Preferred Stock. The change is disclosed as a material modification to security holder rights under Item 3.03.

Schedule 13G shows Bank of America Corporation reports beneficial ownership of 494,341 shares of Aptevo Therapeutics Inc. common stock, representing 15.0% of the outstanding class based on 3,287,918 shares. The holdings are reported as shared voting and shared dispositive power for 494,341 shares; no sole voting or dispositive power is claimed. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Bank of America Corporation, together with Bank of America N.A. and BofA Securities, Inc., filed a joint Form 4 to report that their combined beneficial ownership in Aptevo Therapeutics Inc. (APVO) has fallen below 10%. The filing lists the reporting entities' Charlotte, NC addresses and includes authorized signatures dated 10/03/2025. The statement explains the purpose is to indicate these entities are no longer subject to Section 16 reporting obligations because their ownership decreased under the 10% threshold.

Bank of America Corporation and two wholly owned subsidiaries — Bank of America N.A. and BofA Securities, Inc. — jointly filed an initial Form 3 reporting beneficial ownership in Aptevo Therapeutics Inc. (APVO). The filing shows a combined indirect holding of 27 shares of Aptevo common stock, held by the subsidiaries and attributable to the parent through ownership of those subsidiaries. The filing notes the reporting owners may have temporarily held voting and dispositive power over additional shares due to short-term stock borrowings, and clarifies the filing is not an admission of acting as a group under Section 13(d).

Point72 entities and Steven A. Cohen disclosed beneficial ownership of 299,944 shares of Aptevo Therapeutics Inc. common stock, representing 9.1% of the class as of the close of business on September 16, 2025. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through their management of Point72 Associates, while Mr. Cohen controls those entities. The statement includes a certification that the shares were not acquired to change or influence control of the issuer. The reporting parties executed a joint filing agreement (Exhibit 99.1) and provided principal business address information.